The U.S. Health and Human Services and the Justice Departments are bringing more resources to their crack down on False ...

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target ...

Agonists of immune checkpoint modulators for treating autoimmune and inflammatory disorders have shown high potential in ...

In subpoenaing a former Pfizer Inc. official to appear before the U.S. House Judiciary Committee July 22, Judiciary Chair Jim Jordan, R-Ohio, signaled legislative steps Congress may take in response ...

Kardium Inc. raised C$340 million (US$250 million) in an oversubscribed financing round to support commercialization of its Globe pulsed field ablation system for atrial fibrillation. Notably, the ...

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating ...

A healthy life for a healthy heart is a popular saying. However, even when following good habits, heart health can be already compromised from the very earliest stages of development. Maternal cells ...

Puretech Health plc’s rollout May 20 of more phase IIb data with deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis ...

Researchers at Caedo Oncology AS and collaborators have recently developed a new chimeric bifunctional anti-CD47 (IgG4) ...

Researchers at Washington University reported the preclinical validation of [18F]FQ-NeuroROS, a redox-sensitive reporter ...

Protagonist Therapeutics Inc. has nominated PN-477 as a development candidate for the treatment of obesity. Copyright ©2025.

It may be a year later than originally planned, but Regeneron Pharmaceuticals Inc. is set to commercialize Lynozyfic (linvoseltamab) in the U.S. following FDA approval for use in adults with relapsed ...